Radiosensitization of a mouse tumour by Ro 03-8799: acute and protracted administration.
The nitroimidazole Ro 03-8799 has been tested as a sensitizer of hypoxic tumour cells, using regrowth delay of a mouse mammary carcinoma. This drug has a short biological half-life and has previously proved to be less promising in tumour experiments than was predicted from in vitro studies and from artificially hypoxic skin. The postulate that this might result from the delay in penetrating to poorly vascularized tumour regions has been tested by maintaining constant blood and tumour levels for 2 hours before irradiation, using an infusion pump. For equivalent gross tumour concentrations at the time of irradiation there was no significant difference in the radiosensitization achieved with a single dose or with prolonged administration. This indicates that slow penetration of the drug is not a problem.
D000818:Animals; D007274:Injections, Intraperitoneal; D008321:Mammary Glands, Animal; D008325:Mammary Neoplasms, Experimental / Q000188:drug therapy / Q000532:radiotherapy*; D051379:Mice; D009368:Neoplasm Transplantation; D009369:Neoplasms / Q000662:veterinary; D009593:Nitroimidazoles / Q000008:administration & dosage*; D011838:Radiation-Sensitizing Agents / Q000008:administration & dosage*
D009593:Nitroimidazoles; D011838:Radiation-Sensitizing Agents; C033815:pimonidazole